Brief: Poseida Therapeutics Says Presents Preclinical Data From P-FVIII-101 Gene Therapy For Hemophilia A

Poseida Therapeutics

11/12/2022 15:35

Dec 11 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * PRESENTS PRECLINICAL DATA FROM P-FVIII-101 GENE THERAPY
FOR
HEMOPHILIA A AT 64TH ASH ANNUAL MEETING & EXPOSITION
    * DATA ESTABLISHES PRECLINICAL PROOF OF PRINCIPLE FOR
TREATMENT OF
HEMOPHILIA A ACROSS ALL AGES, WHICH COULD POTENTIALLY LEAD TO

Source text for Eikon:  ID:nPn6xfDgra 
Further company coverage:  PSTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))